Actively Recruiting
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Led by Electra Therapeutics Inc. · Updated on 2026-03-12
84
Participants Needed
1
Research Sites
145 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.
CONDITIONS
Official Title
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Confirmed diagnosis of relapsed or refractory T cell malignancy
- For cutaneous T cell lymphoma, at least 2 prior systemic therapy lines
- Measurable disease by clinical exam, imaging, or bone marrow biopsy
- Eastern Cooperative Oncology Group performance status of 2 or less
- Expected life expectancy greater than 6 months as judged by investigator
You will not qualify if you...
- Eligible for standard treatments with proven benefit for relapsed/refractory T cell malignancies
- Organ dysfunction as defined by the study protocol
- Diagnosis of hemophagocytic lymphohistiocytosis based on HLH2004 criteria
- Receiving or planning to start immunotherapy or immune effector cell therapies
- Allogeneic stem cell transplant within 100 days and currently on systemic immunosuppressants
- Women who are pregnant, planning pregnancy, or breastfeeding during the study and 60 days after last dose
- Male participants with partners who are women of childbearing potential planning pregnancy during the study and 60 days after last dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
START, Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
Research Team
C
Clinical Trials Electra Clinical Trials Information
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here